IgA Nephropathy clinical trials at University of California Health

5 in progress, 4 open to eligible people

Showing trials for

  • BION-1301 in Adults With IgA Nephropathy

    open to eligible people ages 18 years and up

    Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy

    at UCSF

  • Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.

    at UCLA

  • Atacicept in Subjects with IgA Nephropathy

    open to eligible people ages 18 years and up

    A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)

    at UCLA

  • Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

    open to eligible people ages 18 years and up

    The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.

    at UCLA UCSF

  • LNP023 in Primary IgA Nephropathy Patients

    Sorry, in progress, not accepting new patients

    The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.

    at UCLA

Our lead scientists for IgA Nephropathy research studies include .

Last updated: